WallStSmart
IDXX

IDEXX Laboratories Inc

NASDAQ: IDXX · HEALTHCARE · DIAGNOSTICS & RESEARCH

$553.66
-2.58% today

Updated 2026-04-29

Market cap
$44.08B
P/E ratio
42.36
P/S ratio
10.24x
EPS (TTM)
$13.07
Dividend yield
—
52W range
$465 – $770
Volume
0.5M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

IDEXX Laboratories Inc (IDXX) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$553.66
Consensus
$712.00
+28.60%
2030 Target
$968.23
+74.88%
DCF
$440.68
-47.21% MoS
9 analysts:
5 Buy3 Hold1 Sell

Management guidance

IDEXX guided FY2026 revenue growth of 8%-10% at BofA Summit (Feb 2026), implying revenue of $4.644B-$4.73B for 2026. Management emphasized strong demand for pet diagnostics and recurring revenue acceleration from aging pandemic pet cohorts. CEO Jonathan Mazelsky (new as of 2026) inherits a company with momentum in Cancer Dx initiatives and inVue Dx analyzer pull-through.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$1,651.69
$6.5B Rev × 20x P/S
Base case (2030)
$968.23
$6.5B Rev × 12x P/S
Bear case (2030)
$626.51
$6.5B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$3.7B$3.9B$4.3B$4.7B$5.1B$5.5B$6.0B$6.5B
Revenue growth—6.5%10.4%8.9%8.6%8.4%8.5%8.6%
EPS$10.07$11.25$13.07$14.82$16.71$18.22$19.94$21.84
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$683.46$740.42$854.33$911.28$968.23

Catalysts & risks

Growth catalysts
+ Cancer Dx Panel expansion internationally (UK launch confirmed April 2026; US market penetration accelerating)
+ inVue Dx cell cytology analyzer pull-through driving recurring revenue and margin expansion
+ Aging pandemic pet cohort driving sustained veterinary visit frequency despite near-term visit headwinds
+ New CEO transition (Jonathan Mazelsky) with demonstrated ability to execute growth strategy
+ Investor Day (August 14, 2025) likely to reset expectations on recurring revenue durability and 2027-2030 growth
Key risks
- Veterinary visit decline (16th straight quarter of decline as of March 2026) may compress diagnostic volumes despite higher per-visit spending
- High valuation (43.5x P/E, 10.68x P/S) leaves limited margin for error; recent stock decline of 14% YTD reflects elevated expectations
- Executive departure (Nimrata Hunt, EVP Global Strategy, departing April 2026) signals potential strategic shifts or organizational challenges
- Pet spending normalization post-pandemic if pet ownership stabilizes and emergency/critical care adoption plateaus
- Competition from larger diagnostics players (Danaher, IQVIA) entering pet health space

Methodology

IDEXX Laboratories Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 9 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.